Antidepressant adverse drug reactions in older adults: Implications for RNs and APNs

Geriatric Nursing

Volumn 34, Issue 1, 2013, Pages 53-61

  Mitsch, Amanda L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adverse drug reaction; Antidepressants; Long term care facility; Monoamine oxidase inhibitors; Older adults; Pharmacokinetics; Selective serotonin reuptake inhibitors; Serotonin norepinephrine inhibitors; Tetracyclic; Tricyclic

Indexed keywords

ANTIDEPRESSANT AGENT;

ADVERSE DRUG REACTION; AGED; ARTICLE; CLASSIFICATION; FEMALE; HUMAN; NURSE PRACTITIONER; NURSING; NURSING STAFF; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; NURSE PRACTITIONERS; NURSING STAFF;

EID: 84875371126     PISSN: 01974572     EISSN: 15283984     Source Type: Journal    
DOI: 10.1016/j.gerinurse.2012.08.004     Document Type: Article

References (84)

1. Karkare S.U., Bhattacharjee S., Kamble P., Aparasu R. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriat Pharmacother 2011, 9(2):109-119.
2. Kallenbach L.E., Rigler S.K. Identification and management of depression in nursing facility residents. J Am Med Dir Assoc 2006, 7(7):448-455.
3. Coupland C., Dhiman P., Morriss R., Arthur A., Barton G., Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011, 343:d4551.
4. Barnett S.R. Polypharmacy and perioperative medications in the elderly. Anesthesiol Clin 2009, 27(3):377-389.
5. Bigos K.L., Chew M.L., Bies R.R. Pharmacokinetics in geriatric psychiatry. Curr Psychiatry Rep 2008, 10(1):30-36.
6. Storskrubb T., Aro P., Ronkainen J., et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008, 43(12):1448-1455.
7. Varma S., Sareen H., Trivedi J.K. The geriatric population and psychiatric medication. Mens Sana Monogr 2010, 8(1):30-51.
8. Bull S.A., Hunkeler E.M., Lee J.Y., et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002, 36(4):578-584.
9. Hamad G.G., Helsel J.C., Perel J.M., et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012, 169(3):256-263.
10. McLean A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004, 56(2):163-184.
11. Butler J.M., Begg E.J. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008, 47(5):297-321.
12. Sitar D.S. Aging issues in drug disposition and efficacy. Proc West Pharmacol Soc 2007, 50:16-20.
13. Keltner N.L., Moore R.L. Biological perspectives psychiatric drug-drug interactions: a review. Perspect Psychiatr Care 2010, 46(3):244-251.
14. de Leon J., Armstrong S.C., Cozza K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006, 47(1):75-85.
15. Chemali Z., Chahine L.M., Fricchione G. The use of selective serotonin reuptake inhibitors in elderly patients. Harv Rev Psychiatry 2009, 17(4):242-253.
16. Draper B., Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008, 25(6):501-519.
17. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163(22):2716-2724.
18. Stefanacci R.G., Cavallaro E., Beers M.H., Fick D.M. Developing explicit positive Beers criteria for preferred central nervous system medications in older adults. Consult Pharm 2009, 24(8):601-610.
19. Haney E.M., Chan B.K., Diem S.J., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167(12):1246-1251.
20. Diem S.J., Blackwell T.L., Stone K.L., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167(12):1240-1245.
21. Madhusoodanan S., Alexeenko L., Sanders R., Brenner R. Extrapyramidal symptoms associated with antidepressants-a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010, 22(3):148-156.
22. Salzman C. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. J Clin Psychiatry 1999, 60(suppl 20):30-33.
23. Jacob S., Spinler S.A. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006, 40(9):1618-1622.
24. Wright S.K., Schroeter S. Hyponatremia as a complication of selective serotonin reuptake inhibitors. J Am Acad Nurse Pract 2008, 20(1):47-51.
25. Pacher P., Ungvari Z., Nanasi P.P., Furst S., Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?. Curr Med Chem 1999, 6(6):469-480.
26. Cherin P., Colvez A., Deville de Periere G., Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997, 50(3):313-320.
27. Goryachkina K., Burbello A., Boldueva S., Babak S., Bergman U., Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008, 64(3):275-282.
28. Labos C., Dasgupta K., Nedjar H., Turecki G., Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011, 183(16):1835-1843.
29. de Abajo F.J. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011, 28(5):345-367.
30. Kutscher E.C., Leloux M., Lemon M. Antidepressants in geriatric patients: reduce the risk of GI bleeding. Curr Psychiatry 2010, 9(11):84-86.
31. Poeschla B.D., Bartle P., Hansen K.P. Serotonin syndrome associated with polypharmacy in the elderly. Gen Hosp Psychiatry 2010, 33(3).
32. Somes J., Donatelli N.S. Serotonin syndrome-muscle rigidity and confusion in the older adult. J Emerg Nurs 2012, 38(1):76-78.
33. Mottram P., Wilson K., Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006, (1):CD003491.
34. Gillman P.K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011, 31(1):66-74.
35. Meeks T.W., Culberson J.W., Horton M.S. Medications in long-term care: when less is more. Clin Geriatr Med 2011, 27(2):171-191.
36. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008, 13(10):855-870.
37. Wimbiscus M., Kostenko O., Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 2010, 77(12):859-882.
38. Khouzam H.R. Depression in the elderly: how to treat. Consultant 2012, 52(4):267-278.
39. Klamerus K.J., Parker V.D., Rudolph R.L., Derivan A.T., Chiang S.T. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996, 16(5):915-923.
40. Nichols A.I., Focht K., Jiang Q., Preskorn S.H., Kane C.P. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011, 31(3):155-167.
41. Gribbin J., Hubbard R., Gladman J., Smith C., Lewis S. Serotonin-norepinephrine reuptake inhibitor antidepressants and the risk of falls in older people: case-control and case-series analysis of a large UK primary care database. Drugs Aging 2011, 28(11):895-902.
42. Ruhrmann S., Klosterkotter J., Bodatsch M., et al. Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 2012, 18(4):550-557.
43. Darowski A., Chambers S.A., Chambers D.J. Antidepressants and falls in the elderly. Drugs Aging 2009, 26(5):381-394.
44. Kirby D., Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001, 16(5):484-493.
45. Colucci V.J., Berry B.D. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother 2008, 42(6):882-887.
46. Richter J.A., Patrie J.T., Pop R.P.H., Regan K.A., Peura D.A., Wang A.Y. Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. Gastrointest Endosc 2010, 74(1):22-34.
47. Opatrny L., Delaney J.A., Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008, 66(1):76-81.
48. Tepper S.J. Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice. Headache 2012, 52(2):195-197.
49. Lind A.B., Reis M., Bengtsson F., et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009, 48(1):63-70.
50. D'Empaire I., Guico-Pabia C.J., Preskorn S.H. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?. J Psychiatr Pract 2011, 17(5):330-339.
51. Zhou S.F., Liu J.P., Lai X.S. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009, 16(21):2661-2805.
52. Hrdina P.D., Rovei V., Henry J.F., et al. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Psychopharmacology (Berl) 1980, 70(1):29-34.
53. Nguyen J.K., Fouts M.M., Kotabe S.E., Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006, 4(1):36-41.
54. Porcelli S., Fabbri C., Spina E., Serretti A., De Ronchi D. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 2011, 7(9):1101-1115.
55. Schulz P., Turner-Tamiyasu K., Smith G., Giacomini K.M., Blaschke T.F. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 1983, 33(3):360-366.
56. Meyer-Barner M., Meineke I., Schreeb K.H., Gleiter C.H. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol 2002, 58(4):253-257.
57. Benetello P., Furlanut M., Zara G., Baraldo M. Imipramine pharmacokinetics in depressed geriatric patients. Int J Clin Pharmacol Res 1990, 10(3):191-195.
58. Dawling S., Crome P., Braithwaite R.A., Lewis R.R. Nortriptyline therapy in elderly patients: dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol 1980, 18(2):147-150.
59. Abernethy D.R., Greenblatt D.J., Shader R.I. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985, 232(1):183-188.
60. Schmader K.E., Baron R., Haanpaa M.L., et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc 2010, 85(3 suppl):S26-S32.
61. Diem S.J. Current use of SSRIs and tricyclic antidepressants may increase the risk of non-vertebral fractures in the elderly. Evid Based Ment Health 2009, 12(26).
62. Hayes B.D., Klein-Schwartz W., Barrueto F. Polypharmacy and the geriatric patient. Clin Geriatr Med 2007, 23(2):371-390.
63. Ladino M., Guardiola V.D., Paniagua M. Mirtazapine-induced hyponatremia in an elderly hospice patient. J Palliat Med 2006, 9(2):258-260.
64. Rhondali W., Reich M., Filbert M. A brief review on the use of antidepressants in palliative care. Eur J Hosp Pharm 2012, 19:41-44.
65. Fick D.M., Semla T.P. 2012 American Geriatrics Society Beers Criteria: new year, new criteria, new perspective. J Am Geriatr Soc 2012, 60(4):614-615.
66. Bavbek N., Kargili A., Akcay A., Kaya A. Recurrent hyponatremia associated with citalopram and mirtazapine. Am J Kidney Dis 2006, 48(4):e61-e62.
67. Vieweg W.V., Wood M.A., Fernandez A., Beatty-Brooks M., Hasnain M., Pandurangi A.K. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009, 26(12):997-1012.
68. Trifiro G., Dieleman J., Sen E.F., Gambassi G., Sturkenboom M.C. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol 2010, 30(3):252-258.
69. de Leon J. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Curr Drug Metab 2011, 12(7):635-646.
70. Pilgrim J.L., Gerostamoulos D., Drummer O.H. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med 2011, 125(6):803-815.
71. Malato A., Saccullo G., Iorio A., Ageno W., Siragusa S. Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. Curr Pharm Des 2010, 16(31):3483-3486.
72. Auter R.A. A review of the evidence for the efficacy of anti-embolism stockings (AES) in venous thromboembolism (VTE) prevention. J Orthop Nurs 2009, 13(1):41-49.
73. Gray S.L., LaCroix A.Z., Larson J., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2011, 170(9):765-771.
74. Sumukadas D., Davey P., McMurdo M.E. Recurrent urinary tract infections in older people: the role of cranberry products. Age Ageing 2009, 38(3):255-257.
75. Townsend-Roccichelli J., Sanford J.T., VandeWaa E. Managing sleep disorders in the elderly. Nurse Pract 2010, 35(5):30-37.
76. Pearce S., Ahned N., Varas G.M. A case study of delayed serotonin syndrome: lessons learned. Consult Pharm 2009, 24(1):64-68.
77. Levy H.B., Marcus E.L., Christen C. Beyond the Beers criteria: a comparative overview of explicit criteria. Ann Pharmacother 2010, 44(12):1968-1975.
78. Hamilton H.J., Gallagher P.F., O'Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 2009, 9:5.
79. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therap 1981, 30(2):239-245.
80. Resnick B., Pacala J.T. 2012 Beers criteria. J Am Geriatr Soc 2012, 60(4):612-613.
81. Page R.L., Ruscin J.M. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother 2006, 4(4):297-305.
82. Lund B.C., Carnahan R.M., Egge J.A., Chrischilles E.A., Kaboli P.J. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 2010, 44(6):957-963.
83. Gallagher P., Ryan C., Byrne S., Kennedy J., O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008, 46(2):72-83.
84. Barry P.J., Gallagher P., Ryan C., O'Mahony D. START (screening tool to alert doctors to the right treatment)-an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing 2007, 36(6):632-638.